XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.22.4

Operating Segments and Related Information | 12 Months Ended
--- | ---
Dec. 31, 2022
Segment Reporting [Abstract] |
Operating Segments and Related Information | 20. Operating Segments and Related Information The Company currently has one primary reportable geographic segment - United States and primarily all revenue is derived in the United States. The Company has three reportable operating segments, plus our Other segment, based on management’s organization of the enterprise - Infrastructure, Life Sciences, Spectrum, and Other. We also have included a Non-operating Corporate segment. All inter-segment revenues are eliminated on consolidation. The Company's revenue concentrations of 10% and greater for the periods indicated were as follows:
|  |  |  |  | Years Ended December 31,
| Segment |  |  |  |  |  | 2022 |  | 2021
Customer A | Infrastructure |  |  |  |  |  | 23.8% |  | 13.9%
Summarized financial information with respect to the Company’s operating segments for the periods indicated is as follows (in millions):
|  |  |  | Years Ended December 31,
|  |  |  |  |  | 2022 |  | 2021
Revenue |  |  |  |  |  |  |  |
Infrastructure |  |  |  |  |  | $ | 1,594.3 |  |  | $ | 1,159.7 |
Life Sciences |  |  |  |  |  | 4.3 |  |  | 3.5 |
Spectrum |  |  |  |  |  | 38.7 |  |  | 42.0 |
Total revenue |  |  |  |  |  | $ | 1,637.3 |  |  | $ | 1,205.2 |
|  |  |  | Years Ended December 31,
|  |  |  |  |  | 2022 |  | 2021
Income (loss) from operations |  |  |  |  |  |  |  |
Infrastructure |  |  |  |  |  | $ | 57.5 |  |  | $ | 35.2 |
Life Sciences |  |  |  |  |  | (20.1) |  |  | (19.9) |
Spectrum |  |  |  |  |  | (3.8) |  |  | (0.8) |
Other |  |  |  |  |  | (0.6) |  |  | (2.0) |
Non-operating Corporate |  |  |  |  |  | (19.6) |  |  | (23.1) |
Total income (loss) from operations |  |  |  |  |  | $ | 13.4 |  |  | $ | (10.6) |
|  |  |  | Years Ended December 31,
Reconciliation of the consolidated segment income (loss) from operating consolidated loss from continuing operations before income taxes |  |  |  |  |  | 2022 |  | 2021
Income (loss) from operations |  |  |  |  |  | $ | 13.4 |  |  | $ | (10.6) |
Interest expense |  |  |  |  |  | (52.0) |  |  | (59.1) |
Loss on extinguishment of debt |  |  |  |  |  | — |  |  | (12.5) |
Loss from equity investees |  |  |  |  |  | (1.3) |  |  | (2.8) |
Other (expense) income, net |  |  |  |  |  | (1.2) |  |  | 4.3 |
Loss from continuing operations before income taxes |  |  |  |  |  | $ | (41.1) |  |  | $ | (80.7) |
|  |  |  | Years Ended December 31,
|  |  |  |  |  | 2022 |  | 2021
Depreciation and Amortization |  |  |  |  |  |  |  |
Infrastructure |  |  |  |  |  | $ | 21.0 |  |  | $ | 19.1 |
Infrastructure recognized within cost of revenue |  |  |  |  |  | 15.0 |  |  | 12.2 |
Total Infrastructure |  |  |  |  |  | 36.0 |  |  | 31.3 |
Life Sciences |  |  |  |  |  | 0.3 |  |  | 0.2 |
Spectrum |  |  |  |  |  | 5.8 |  |  | 6.0 |
Non-operating Corporate |  |  |  |  |  | 0.1 |  |  | 0.1 |
Total depreciation and amortization |  |  |  |  |  | $ | 42.2 |  |  | $ | 37.6 |
|  |  |  | Years Ended December 31,
|  |  |  |  |  | 2022 |  | 2021
Capital Expenditures (*) |  |  |  |  |  |  |  |
Infrastructure |  |  |  |  |  | $ | 16.5 |  |  | $ | 18.3 |
Life Sciences |  |  |  |  |  | 0.8 |  |  | 0.5 |
Spectrum |  |  |  |  |  | 3.3 |  |  | 5.3 |
Non-operating Corporate |  |  |  |  |  | 0.1 |  |  | — |
Total |  |  |  |  |  | $ | 20.7 |  |  | $ | 24.1 |
(*) The above capital expenditures exclude assets acquired under capital lease and other financing obligations.
| December 31,
| 2022 |  | 2021
Investments |  |  |
Infrastructure | $ | — |  |  | $ | 0.7 |
Life Sciences | 7.6 |  |  | 10.2 |
Other | 51.9 |  |  | 45.1 |
Total | $ | 59.5 |  |  | $ | 56.0 |
|  | December 31,
|  | 2022 |  | 2021
Equity Method Investments (included in Investments above) |  |  |  |
Infrastructure |  | $ | — |  |  | $ | 0.7 |
Life Sciences |  | 3.0 |  |  | 4.2 |
Other |  | 40.6 |  |  | 33.9 |
Total |  | $ | 43.6 |  |  | $ | 38.8 |
|  | December 31,
|  | 2022 |  | 2021
Total Assets |  |  |  |
Infrastructure |  | $ | 879.3 |  |  | $ | 786.4 |
Life Sciences |  | 15.4 |  |  | 22.0 |
Spectrum |  | 188.2 |  |  | 198.9 |
Other |  | 53.6 |  |  | 48.0 |
Non-operating Corporate |  | 15.2 |  |  | 25.3 |
Total |  | $ | 1,151.7 |  |  | $ | 1,080.6 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration